Literature DB >> 12827231

Increase in tacrolimus trough levels after steroid withdrawal.

Elly M van Duijnhoven1, Johannes M M Boots, Maarten H L Christiaans, Leo M L Stolk, Nasrullah A Undre, Johannes P van Hooff.   

Abstract

Although there are experimental reports of cytochrome P450 3A4 iso-enzyme (CYP3A4) induction by glucocorticoids, there are no clinical reports about an interaction between tacrolimus and steroids. Therefore, tacrolimus trough level and dose were compared after dose-normalization before and after withdrawal of prednisolone. After withdrawal of 5 mg prednisolone, the median tacrolimus dose-normalized level increased by 14% in the retrospective ( n=54), and by 11% in the prospective ( n=8) part of the study. After withdrawal of 10 mg, this increase was 33% ( n=30) and 36% ( n=14), respectively. An additional pharmacokinetic part of the study ( n=8) revealed an 18% increase in AUC ( P=0.05) after withdrawal of 5 mg prednisolone, which is compatible with a reduced metabolism after steroid withdrawal. The significant increase in tacrolimus exposure after steroid withdrawal may on the one hand counteract the reduction in immunosuppression intended by steroid withdrawal, and, on the other hand, may result in an increase of serum creatinine which could be misinterpreted as rejection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12827231     DOI: 10.1007/s00147-003-0615-1

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  22 in total

1.  The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers.

Authors:  Michael A Tortorici; Virginia Parks; Kyle Matschke; Joan Korth-Bradley; Alain Patat
Journal:  Eur J Clin Pharmacol       Date:  2012-10-04       Impact factor: 2.953

2.  The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation.

Authors:  P Stratta; M Quaglia; T Cena; R Antoniotti; R Fenoglio; A Menegotto; D Ferrante; A Genazzani; S Terrazzino; C Magnani
Journal:  Eur J Clin Pharmacol       Date:  2011-11-20       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

4.  Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit.

Authors:  Hylke de Jonge; Thomas Vanhove; Henriëtte de Loor; Kristin Verbeke; Dirk R J Kuypers
Journal:  Br J Clin Pharmacol       Date:  2015-08-03       Impact factor: 4.335

5.  Early steroid withdrawal in pediatric renal transplant: five years of follow-up.

Authors:  Angela Delucchi; Marcela Valenzuela; Ana M Lillo; Jose Luis Guerrero; Francisco Cano; Marta Azocar; Pedro Zambrano; Paulina Salas; Viola Pinto; Mario Ferrario; Jorge Rodríguez; Gabriel Cavada
Journal:  Pediatr Nephrol       Date:  2011-06-22       Impact factor: 3.714

Review 6.  Minimization of steroids in kidney transplantation.

Authors:  Arthur J Matas
Journal:  Transpl Int       Date:  2008-07-24       Impact factor: 3.782

7.  The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.

Authors:  Agnieszka A Prytuła; Karlien Cransberg; Antonia H M Bouts; Ron H N van Schaik; Huib de Jong; Saskia N de Wildt; Ron A A Mathôt
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

8.  Evaluation of tacrolimus abbreviated area-under-the-curve monitoring in renal transplant patients who are potentially at risk for adverse events.

Authors:  Yuen Yi Hon; Christine E Chamberlain; David E Kleiner; Michael S Ring; Douglas A Hale; Allan D Kirk; Roslyn B Mannon
Journal:  Clin Transplant       Date:  2010 Jul-Aug       Impact factor: 2.863

9.  Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients.

Authors:  Shigeru Satoh; Hideaki Kagaya; Mitsuru Saito; Takamitsu Inoue; Masatomo Miura; Kazuyuki Inoue; Kazuyuki Numakura; Norihiko Tsuchiya; Hitoshi Tada; Toshio Suzuki; Tomonori Habuchi
Journal:  Br J Clin Pharmacol       Date:  2008-04-22       Impact factor: 4.335

Review 10.  Steroid elimination-who, when, how?

Authors:  A J Matas
Journal:  Transplant Proc       Date:  2008-12       Impact factor: 1.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.